This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2003.
Company Filing History:
Years Active: 2003
Title: Elsie Van Bogaert: Innovator in Pharmaceutical Formulations
Introduction
Elsie Van Bogaert is a notable inventor hailing from Bornem, Belgium. She has made significant contributions to the field of pharmaceutical formulations, particularly through her innovative work with high amylose starch. Her research and inventions have paved the way for advancements in controlled-release drug delivery systems.
Latest Patents
Elsie holds a patent for her invention titled "Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture." This patent describes a novel form of cross-linked high amylose starch that serves as an excipient in controlled-release pharmaceutical formulations. The invention outlines a process that includes cross-linking and chemical modification of high amylose starch, followed by gelatinization and drying to produce a powder suitable for use in tablets. This innovative excipient enhances the effectiveness of pharmaceutical agents by allowing for controlled release.
Career Highlights
Throughout her career, Elsie has demonstrated a commitment to advancing pharmaceutical technology. Her work has not only resulted in a patent but has also contributed to the broader understanding of excipients in drug formulations. Her innovative approach to modifying high amylose starch showcases her expertise and dedication to improving pharmaceutical products.
Collaborations
Elsie has collaborated with notable colleagues in her field, including Francois Chouinard and Roland Herwig Friedrich Beck. These collaborations have likely enriched her research and contributed to the successful development of her patented invention.
Conclusion
Elsie Van Bogaert's contributions to the field of pharmaceutical formulations through her innovative patent highlight her role as a leading inventor. Her work with cross-linked high amylose starch represents a significant advancement in controlled-release drug delivery systems.